Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Ricardo Hitt(Research Institute Hospital 12 de Octubre), Juan Jesús Cruz, Antonio Irigoyen López(Hospital Universitario Virgen de las Nieves), José Á. García-Sáenz(Hospital Clínico San Carlos), Juan J. Grau(Hospital Clínic de Barcelona), H. Cortés-Funes(Centre Hospitalier René-Dubos)

Annals of Oncology

August 24, 2011

10.1093/annonc/mdr367

Cited by 222

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

|Journal of Clinical Oncology|2000|3.8k

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

|New England Journal of Medicine|2008|3.7k

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

|UCL Discovery (University College London)|1997|1k

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

|Journal of Clinical Oncology|2005|491

Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

|Journal of Clinical Oncology|2005|454